Clinical Trial

Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies

Study acronym: KCAT19
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
KCAT19 is a single-centre, non-randomised, open-label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age 16-65 years) with high risk, relapsed/refractory (r/r) B cell malignancies.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-08-12
notable Primary completion pushed: 2024-11 -> 2027-02 2026-08-12
minor Completion pushed: 2034-11 -> 2040-02 2026-08-12
Trial Details
NCT Number NCT05391490
Lead Sponsor University College, London
Conditions Blood Cancer
Enrollment 12 participants
Start Date 2023-02-06
Primary Completion 2027-02 (estimated)
Study Completion 2040-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-11